Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NP58
UPID:
ABCB6_HUMAN
Alternative names:
ABC-type heme transporter ABCB6; Mitochondrial ABC transporter 3; P-glycoprotein-related protein; Ubiquitously-expressed mammalian ABC half transporter
Alternative UPACC:
Q9NP58; O75542; Q49A66; Q59GQ5; Q6ZME6; Q96ME8; Q9HAQ6; Q9HAQ7
Background:
ATP-binding cassette sub-family B member 6 (ABCB6) is a pivotal ATP-dependent transporter, facilitating the movement of porphyrins across cellular membranes and contributing to heme biosynthesis and iron homeostasis. Its roles extend to melanogenesis, where it is crucial in the early steps, and providing cellular resistance against various toxic substances, including heavy metals and chemotherapeutic agents.
Therapeutic significance:
ABCB6 is linked to diseases such as Microphthalmia, isolated, with coloboma, 7, Dyschromatosis universalis hereditaria 3, and Pseudohyperkalemia, familial, 2, due to red cell leak. Understanding the role of ABCB6 could open doors to potential therapeutic strategies for these conditions, highlighting its importance in medical research.